NCT02061865View on ClinicalTrials.gov

Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Neovascular Wet Age-related Macular Degeneration (AMD)

Interventions

DRUG

REGN2176-3

Trial Locations (4)

Unknown

Beverly Hills

Colorado Springs

Boston

Houston

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT02061865 - Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD | Biotech Hunter | Biotech Hunter